Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03470259
Other study ID # NL62817.042.17
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 20, 2018
Est. completion date December 31, 2019

Study information

Verified date April 2024
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almost 50 % of papillary thyroid cancer (PTC) patients have central lymph node metastases (CLNM), which are associated with a high risk of persistent or recurrent disease. However, the practice of performing a prophylactic central lymph node dissection (PCLND) routinely remains controversial. The proponents argue that without a PCLND, PTC patients with positive lymph nodes have an increased risk of local recurrence, and postponed node dissection leads to with 5-6 fold higher risk of morbidity. If performed, PCLND in clinical node negative patients increases staging to pN1 in more than 50% of the cases without increasing survival. The complication rate in PCLND is lower when compared to a technically challenging re-exploration in recurrent disease, with reported incidences of 0.6% and 7.3-20%, respectively. Opponents of routine PCLND point out the lack of randomized clinical trials and object to treatment-induced hypo-parathyroidism and recurrent nerve damage for the N0 patients. Currently, no diagnostic tool is available which reliably identifies these patient categories. Therefore, there is a clear need for novel diagnostic imaging modalities that overcome this issue. Molecular Fluorescence Guided Surgery (MFGS) is potentially such a diagnostic tool. The administration of NIR fluorescent tracers can increase detection accuracy of cancer and nodal metastatic tissue using macroscopic MFGS. Therefore, we aimed to identify a GMP-produced near infrared (NIR) tracer that potentially has a high target-to-background ratio in PTC compared to normal thyroid tissue. Tyrosine-protein kinase Met (c-Met) is significantly upregulated at the protein level in PTC compared to normal thyroid tissue. The investigators therefore hypothesize that the GMP-produced NIR-fluorescent tracer EMI-137 (targeting c-Met, peak emission at 675 nm range) might be useful for intraoperative imaging of PTC and nodal metastases. The investigators' aim is to investigate if the administration of EMI-137 is a feasible approach to detect PTC nodal metastases. Ultimately, this method might be useful to improve patient selection for CLND. Eventually, we might also be able to visualize multifocality, more selective lateral neck dissections and asses residual tissue after thyroidectomy. Ultimately, all of these strategies may reduce overtreatment, morbidity, and costs while maintaining the same or better effectiveness with a lower recurrence rate and improved quality of life.


Description:

See brief summary


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years, eligible for surgery 2. Bethesda VI fine needle aspiration (FNA) thyroid or FNA proven PTC metastasis (primary or recurrence). 3. Scheduled to undergo central and/or lateral lymph node dissection with or without thyroidectomy as discussed in the Multi-Disciplinary Thyroid Board. 4. WHO performance score of 0-2. 5. Written informed consent. 6. Mentally competent person who is able and willing to comply with study procedures. 7. For female subjects who are of childbearing potential are premenopausal with intact reproductive organs or are less than two years post-menopausal: - A negative serum pregnancy test prior to receiving the tracer - Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter. Exclusion Criteria: 1. Pregnancy or breast feeding 2. Advanced stage thyroid cancer not suitable for surgical resection 3. Medical or psychiatric conditions that compromise the patient's ability to give informed consent 4. Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment 5. The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months 6. History of myocardial infarction (MI), TIA, CVA, pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment 7. Any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to IMP administration.

Study Design


Intervention

Drug:
IV adminstration of EMI-137
Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
Device:
Multispectral Fluorescence Reflectance Imaging
A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
Spectroscopy
A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen
Netherlands Erasmus Medical Center Rotterdam

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The feasibility of Molecular Fluorescence Guided Surgery using EMI-137 To determine the optimal dose of the c-Met targeting NIRF tracer EMI-137 for an adequate TBR in PTC lymph nodes metastases using 3, and possibly 4, different dosages op EMI-137. From tracer administration until after data analyses which will take up to 1.5year
Secondary Safety of using EMI-137 through monitoring vital signs To evaluate the safety of EMI-137 through monitoring vital signs for evaluating possible (severe) adverse events. 1 day
Secondary Safety of using EMI-137 through monitoring injection site To evaluate the safety of EMI-137 through monitoring the injection site for evaluating possible (severe) adverse events. 1 day
Secondary Feasibility of MFGS for detecting nodal metastasis To evaluate the feasibility of MFGS for the assessment of PTC and nodal metastasis by calculating target-to-background ratio. Up to one year
Secondary Feasibility of spectroscopy for detecting fluorescence of PTC and lymph nodes To determine the feasibility of ex vivo spectroscopy measurements of PTC and lymph nodes for quantification of the fluorescence signal of EMI-137 Up to one year
Secondary Validation of flourescence To correlate and validate fluorescence signals detected ex vivo with histopathology and immunohistochemistry by determining if high flourescence areas show tumorcells in pathological examination. Up to one year
Secondary Distribution of EMI-137 To evaluate the distribution of EMI-137 on a microscopic level using fluorescence microscopy. Up to 1.5 year
Secondary Sensitivity and specificity of EMI-137 To quantify sensitivity and specificity of EMI-137 for PTC and nodal metastasis in order to make a power size calculation for a possible subsequent diagnostic accuracy study. Up to 1.5 year
See also
  Status Clinical Trial Phase
Completed NCT03280719 - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions N/A
Active, not recruiting NCT04300673 - Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients Phase 1/Phase 2
Completed NCT04260139 - Lymph Node Yield in Colon Cancer Resection Specimens
Not yet recruiting NCT03632746 - Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
Active, not recruiting NCT03776591 - Open D3 Right Hemicolectomy Compared to Laparoscopic CME for Right Sided Colon Cancer N/A
Recruiting NCT05078853 - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Recruiting NCT03715686 - To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes N/A
Recruiting NCT03280134 - A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer N/A
Recruiting NCT04117139 - The Diagnostic Value of PET/MRI in Head and Neck Cancer N/A
Recruiting NCT04882618 - Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer. Phase 4
Recruiting NCT05670574 - Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors N/A
Active, not recruiting NCT04611997 - IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Phase 3
Recruiting NCT04744506 - Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy N/A
Recruiting NCT03830242 - Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer. N/A
Recruiting NCT04959604 - Lymph Node Mapping Via Flourescent Dye in Colon Cancer N/A
Active, not recruiting NCT04419935 - Lymphadenectomy in NSCLC With and Without Adjuvant Therapy
Enrolling by invitation NCT04322331 - Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer
Recruiting NCT03868215 - Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node Metastasis
Recruiting NCT04337333 - Two-in-one Covered and Uncovered Metal Stent N/A
Completed NCT04068636 - Sentinel Node in Larynx and Pharynx Cancers N/A